Cornell University spinout AvantGuard develops antimicrobial chemistry for protecting skin, medical devices, and other surfaces from pathogens and biofilms. Founded as Halomine in 2018, the company built its Avantamine platform to mimic the pathogen-fighting properties of taurine chloramine while offering a reported three- to five-year shelf life and less corrosion and irritation than conventional chlorine products. Its current development focus includes solutions for the drug-resistant fungal pathogen Candida auris.
FDA Investigational New Drug (IND) application
compliance_program
Qualified Infection Disease Product (QIDP) designation
compliance_program